Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD), has provided an update on
the Company’s two active clinical trials in IMP321. Prima is
pleased to advise that clinical studies of IMP321 are progressing
well.
TACTI-mel (Two ACTive
Immunotherapeutics in melanoma), the Company’s Australian melanoma
trial, has completed recruitment of the first two cohorts of six
patients and has now commenced recruitment of the third cohort. No
dose limiting toxicity has been observed in any patient.
Patients with unresectable or metastatic melanoma will be
dosed with IMP321 in combination with an approved checkpoint
inhibitor (anti-PD-1 antibody) after the patient did not optimally
respond to the checkpoint inhibitor alone.
As previously disclosed, data from the first
cohort was presented in March at the ICI conference in Boston. This
included one patient with complete remission after progress on
anti-PD-1 therapy alone. This patient remains in complete
remission, while other patients from the first cohort have shown a
partial remission and stabilizations of disease. The company
expects to present a data set from the first two cohorts at the
following conferences:
- World Immunotherapy Congress, Basel, Switzerland on October
31st, 2017; and
- SITC, Society for Immunotherapy of Cancer, National Harbor, MD,
USA, November 08-12, 2017
Data from all three cohorts is expected in H1
2018.
AIPAC (Active Immunotherapy
PAClitaxel), started the recruitment of the randomized part of the
study in January 2017. In addition to centres in Belgium and
the Netherlands, patient recruitment has also now commenced in
Poland and Hungary, with the United Kingdom to follow in due
course. In total, 19 clinical sites have been activated and more
activations will follow in the coming months. The study is expected
to be fully recruited in H1 2018.
As announced earlier in June, data from the
open-label safety run-in cohort of 15 patients, who received 6 and
30 mg doses of IMP321 in combination with paclitaxel, were
presented at ASCO in Chicago. Final results of the 15 patients from
the safety run-in phase of AIPAC are expected in the fourth quarter
of 2017.
IMP321 Partnering Update
Prima’s Chinese partner for IMP321, EOC Pharma,
an oncology focused affiliate of Eddingpharm applied in first
quarter of 2017 for an Investigational New Drug (IND) in China, as
a preparation to start clinical trials. Recent positive changes in
the Chinese regulatory environment provide the possibility to speed
up the development of IMP321 in China. Prima and EOC Pharma will
work together to advance this promising drug to meet unmet medical
need in China.
CYTLIMIC, the Japanese NEC spin off with which
Prima has a collaboration agreement, presented a poster at ASCO
(http://abstracts.asco.org/199/AbstView_199_183394.html) which
showed the results of their T-cell based therapeutic cancer vaccine
with IMP321 as an adjuvant to the vaccine.
About Prima BioMed
Prima BioMed is listed on the Australian Stock
Exchange, and on the NASDAQ in the US. For further information
please visit www.primabiomed.com.au
For further information please contact:
U.S. Investors:
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Australian Investors/Media:
Mr Matthew Gregorowski, Citadel-MAGNUS
+61 (2) 8234 0100; mgregorowski@citadelmagnus.com
Immutep Limited (NASDAQ:PBMD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Immutep Limited (NASDAQ:PBMD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024